Presentations and Publications EO1001: A first-in-class irreversible pan-ErbB inhibitor with excellent brain penetration Edison Oncology January 4, 2020
Presentations and Publications Preclinical development of EO1001, a novel irreversible brain penetrating pan-ErbB inhibitor (Oral Presentation) Edison Oncology August 4, 2019
